Is secukinumab effective for active, moderate-to-severe Graves orbitopathy?

In a randomised trial, secukinumab did not improve clinical response compared with placebo at 16 weeks.

Randomised trial · Journal of Clinical Endocrinology & Metabolism 2026

Reference: Wolf J, et al. Secukinumab in moderate-to-severe Graves orbitopathy: a randomised, double-blind, placebo-controlled multicentre study. J Clin Endocrinol Metab. 2026;111(5):1248-1257. doi:10.1210/clinem/dgaf655. PMID: 41362233. https://pubmed.ncbi.nlm.nih.gov/41362233/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en